Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

14854 results about "Buffer solution" patented technology

A buffer solution (more precisely, pH buffer or hydrogen ion buffer) is an aqueous solution consisting of a mixture of a weak acid and its conjugate base, or vice versa. Its pH changes very little when a small amount of strong acid or base is added to it. Buffer solutions are used as a means of keeping pH at a nearly constant value in a wide variety of chemical applications. In nature, there are many systems that use buffering for pH regulation. For example, the bicarbonate buffering system is used to regulate the pH of blood.

Catheter devices and methods for their use in the treatment of calcified vascular occlusions

Catheter devices and methods for their use in enhancing fluid flow through a vascular site occupied by a vascular occlusion are provided. The subject catheter devices include at least a first, second and third lumen, where: (a) the first lumen is used for delivery of an acidic dissolution solution to the vascular site; (b) the second lumen is used for delivery of a buffer solution to the vascular site; and (c) the third lumen is used for removal of fluid from the vascular site. In many preferred embodiments, the first, second and third lumens are coaxial. In practicing the subject methods, the vascular site is flushed simultaneously with an acidic dissolution fluid and a buffer solution, where flushing is carried out in a manner such that only a surface of the vascular occlusion is contacted with the acidic dissolution fluid and the remainder of the vascular site is not contacted with fluid having a pH that is lower than about 4. Flushing is carried out in this manner for a period of time sufficient for fluid flow through the vascular site to be enhanced, e.g. increased or established. The subject catheter devices and methods find use in the treatment of a variety of different vascular diseases characterized by the presence of calcified vascular occlusions, including peripheral and coronary vascular diseases.
Owner:CARDINAL HEALTH SWITZERLAND 515 GMBH

Methods and apparatus for minimizing evaporation of sample materials from multiwell plates

Methods and devices for reducing evaporation of sample materials from the wells of multiwell plates are disclosed which find particular utility when the plates are placed in a stacked configuration. An example of the methods includes providing at least a first multiwell plate which is configured to be placed in a stacked configuration with at least one second multiwell plate, the at least first multiwell plate having a plurality of wells for receiving sample material therein and opposing side walls which extend around the plate and which define a ridge spaced inwardly of the side walls and extending around the plate between the side walls and the plurality of wells, the method including at least partially filling the ridge with a liquid such as water or buffer solution. The ridge can include one or more ribs which extend upwardly from a lower surface of the ridge to help reduce sloshing of the liquid contained within the ridge and to add structural strength and rigidity to the multiwell plate. The second multiwell plate can be provided with a downwardly extending flange which extends around a lower surface of the plate and which is configured to be removably received by the ridge of the at least first multiwell plate such that when the second multiwell plate is removably positioned on top of the at least first multiwell plate in a stacked configuration, the flange extends at least partially into the ridge and contacts the liquid to thereby create a substantial evaporation barrier to minimize evaporation of sample liquids in the wells of the at least first multiwell plate.
Owner:CALIPER TECH

DNA (Deoxyribose Nucleic Acid) sequencer

The invention discloses a DNA (Deoxyribose Nucleic Acid) sequencer which comprises a supporting table, a plurality of vibration dampers, a vibration damping plate, a reaction bin assembly, a CCD (Charge Coupled Device) camera, a two-dimensional regulation supporting device and a medicament supply assembly, wherein the vibration damping plate is connected with the supporting table by a plurality of vibration dampers; the reaction bin assembly is fixedly arranged on the vibration damping plate and is used for performing the DNA sequencing reaction; the CCD camera is used for acquiring an optical signal; the two-dimensional regulation supporting device is used for supporting the CCD camera; and the medicament supply assembly is arranged on the supporting table and is used for providing reagents and buffer solution for the reaction bin assembly. According to the DNA sequencer disclosed by the invention, by the arrangement of a plurality of reaction bins and the matching of the two-dimensional regulation supporting device capable of carrying out two-dimensional regulation and the medicament supply assembly capable of supplying the reagents for a plurality of reaction bins, the aim of simultaneously performing a plurality of reactions is fulfilled, a plurality of samples can be simultaneously sequenced and the DNA sequencing efficiency is greatly improved.
Owner:BEIJING INST OF GENOMICS CHINESE ACAD OF SCI CHINA NAT CENT FOR BIOINFORMATION +1

Method for chemically modifying inorganic filler with graphene oxide, product and application

The invention discloses a method for chemically modifying inorganic filler with graphene oxide and a product. The method comprises the following steps: performing surface hydroxylation treatment and silane coupling agent treatment on the inorganic filler; maintaining the pH of a graphene oxide solution at 5.8-6.0 with an MES buffer solution; sequentially adding EDC and NHS, and performing ultrasonic treatment for 1-3 hours; adding the treated inorganic filler, and performing an amidation reaction at room temperature; and after the reaction, filtering, washing and drying to obtain the graphene oxide modified inorganic filler. The invention also discloses a method for preparing an inorganic filler/epoxy resin composite by use of the product. The process flow of the method disclosed by the invention is simple and environmentally friendly; the GO is connected to the surface of the inorganic filler by a chemical modification process, and the firm covalent bond combination between the GO and inorganic particles is generated, so that the interface adhesiveness and mechanical strength between the inorganic filler and the polymer are enhanced, and a new idea is provided to the modification of an inorganic filler surface and the preparation of a high-performance composite.
Owner:UNIV OF JINAN

Cervical exfoliated cell preservative fluid

The invention relates to a cervical exfoliated cell preservative liquid, the preservative liquid comprises the following components with the contents (by weight): 20 percent to 50 percent of alcohols; 15 percent to 50 percent of anti-aggregation reagent; 5 percent to 10 percent of buffer solution; 1 percent to 20 percent of ion strength maintaining reagent; 0.01 percent to 0.5 percent of anti-microbial reagent; 0.1 to 5 percent of mucus dissolving reagent; and 0 to 0.5 percent of cleaning agent. Compared with the prior art, the preservative liquid can not only lead cells to maintain the shape in an in vitro liquid suspension environment, minimize the protein precipitation, dissolve larger protein substances, such as blood and mucus, and reduce the cell aggregation, but can also selectively eliminate or reduce red cells, effectively kill microbes, prevent the activity of reverse transcriptase and retain the integrity of nucleic acids and proteins for facilitating the later analysis; in addition, the preservative liquid can greatly reduce the costs of consumptive materials for the TCT detection, improve the sensitivity and the specificity of the cervical cancer screening and accelerate the promotion and the popularization of the TCT technology in a medical system.
Owner:SHANGHAI ADICON CLINICAL LAB LNC

Method for extracting and purifying nucleic acid from samples by magnetic beads

The invention relates to a method for extracting and purifying nucleic acid from samples by magnetic beads, which comprises the following steps: (1) magnetic bead treatment: modifying the magnetic beads by peptide-oligonucleotide; (2) cell lysis: adding the sample containing target nucleic acid and needing to be separated into a centrifuge tube, and then adding lysis buffer to lyse the cells; (3)nucleic acid adsorption: adding the magnetic beads modified by the peptide-oligonucleotide into the solution to lead the nucleic acid to be adsorbed on the surfaces of the magnetic beads; placing thecentrifuge tube into a magnetism separation machine to lead the magnetic beads to be adsorbed on the tube side; (4) impurities removal: adding aqueous phase buffer solution to wash the magnetic bead which are adsorbed with the nucleic acid on the surfaces and adsorbed on the tube side so as to separate other impurities on the magnetic bead; and (5) nucleic acid recovery: directly taking the nucleic acid adsorbed on the surfaces of the magnetic beads as the template for PCR amplification, or adding elution buffer to lead the nucleic acid molecules adsorbed on the surfaces of the magnetic beadsto be released into the buffer for downstream experiments. The magnetic beads used by the method can be reserved at the temperature of 4 DEG C or -20 DEG C, and have convenient transport, high adsorption efficient and lower cost. The nucleic acid extracted and purified by the method has wide application range.
Owner:SANSURE BIOTECH INC

Preparation method of polyinosinic-polycytidylic acid dry powder

The invention provides a preparation method of polyinosinic-polycytidylic acid dry powder. The method comprises the following steps: (1) respectively dissolving polyinosinic acid and polycytidysic acid in a phosphate buffer solution, mixing the solution, adding a stabilizer, uniformly mixing the stabilizer and the solution, and performing heat preservation on the mixture at the temperature of 40-100DEG C; (2) naturally cooling the reaction liquid obtained in the step (1), mixing the reaction liquid with an organic solvent, standing for precipitating, and drying the precipitate, thereby obtaining the polyinosinic-polycytidylic acid dry powder. The preparation method has the beneficial effects that the prepared polyinosinic-polycytidylic acid dry powder has a complete double-helix structural features and physiological activity, the quality and the stability are better than those of the polyinosinic-polycytidylic acid at a solution state, a stronger enzymolysis-resisting performance can be achieved compared with the bare polyinosinic-polycytidylic acid after entering a living body, so that the curative effect can be enhanced. The polyinosinic-polycytidylic acid is purified in the process for making the polyinosinic-polycytidylic acid solution into the dry powder, a plurality of small-molecular-weight substances and impurities can be removed, the toxic and side effects can be reduced, and the quality of the polyinosinic-polycytidylic acid can be improved.
Owner:美亚药业海安有限公司

Latex enhanced turbidimetric immunoassay kit of quantitatively detecting procalcitonin PCT

The invention relates to a latex enhanced turbidimetric immunoassay kit of quantitatively detecting procalcitonin PCT. The kit comprises an R1 reagent, an R2 reagent and a calibrator, wherein the R1 reagent comprises a protecting agent, a reaction enhancing agent, a preservative and buffer solution; the R2 reagent comprises a protecting agent, a preservative, buffer solution and anti-human PCT antibody coated sensitization polystyrene latex particles; the calibrator comprises a protecting agent, a preservative, buffer solution and PCT recombinant protein; the human PCT antibody in the R2 reagent is linked with polystyrene latex particles through streptavidin-biotin; and the particle diameter of the latex particles in the R2 reagent is 40-500 nm. The kit can be used on a biochemical analyzer and a scatter turbidimetry analyzer for quantitatively detecting the PCT content in human blood. The invention provides the PCT detection kit which has the advantages of convenience, quickness, high sensitivity, strong specificity and accurate quantification; and the kit has high instrument compatibility, is low in detection cost and meets the requirements on PCT turbidimetric products in clinical use.
Owner:NANJING NORMAN BIOLOGICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products